The brand name and generic drug industries once again came under congressional fire for increases in drug pricing, this time for medicines to treat opioid addiction and overdose.
What's Driving Price Increases For Addiction Treatment Drugs?
At House hearing, PhRMA representative cites introduction of innovative delivery systems while GPhA exec points to manufacturing costs; state attorneys general file Suboxone 'product hopping' suit.